Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Co's existing focus is on the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus. Co.'s product candidate for the treatment of COVID-19 is bemnifosbuvir. For the treatment of chronic HCV infection, Co. is developing a combination of bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A inhibitor. Co. is developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. The AVIR average annual return since 2020 is shown above.
The Average Annual Return on the AVIR average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AVIR average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AVIR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|